0001179110-21-000538.txt : 20210112
0001179110-21-000538.hdr.sgml : 20210112
20210112161550
ACCESSION NUMBER: 0001179110-21-000538
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210108
FILED AS OF DATE: 20210112
DATE AS OF CHANGE: 20210112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hill Emily Luisa
CENTRAL INDEX KEY: 0001778279
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35969
FILM NUMBER: 21523660
MAIL ADDRESS:
STREET 1: C/O PTC THERAPEUTICS, INC.
STREET 2: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001070081
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043416587
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
BUSINESS PHONE: 9082227000
MAIL ADDRESS:
STREET 1: 100 CORPORATE COURT
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080-2449
FORMER COMPANY:
FORMER CONFORMED NAME: PTC THERAPEUTICS INC
DATE OF NAME CHANGE: 19980909
4
1
edgar.xml
FORM 4 -
X0306
4
2021-01-08
0
0001070081
PTC THERAPEUTICS, INC.
PTCT
0001778279
Hill Emily Luisa
C/O PTC THERAPEUTICS, INC.
100 CORPORATE COURT
SOUTH PLAINFIELD
NJ
07080
0
1
0
0
Chief Financial Officer
Common Stock
2021-01-08
4
M
0
2430
30.86
A
26552
D
Common Stock
2021-01-08
4
S
0
2430
69.75
D
24122
D
Common Stock
2021-01-08
4
M
0
3825
11.23
A
27947
D
Common Stock
2021-01-08
4
S
0
3825
69.75
D
24122
D
Common Stock
2021-01-08
4
M
0
10500
18.01
A
34622
D
Common Stock
2021-01-08
4
S
0
10500
69.75
D
24122
D
Common Stock
2021-01-08
4
M
0
9278
33.02
A
33400
D
Common Stock
2021-01-08
4
S
0
9278
69.75
D
24122
D
Stock Option (Right To Buy)
30.86
2021-01-08
4
M
0
2430
30.86
D
2026-01-03
Common Stock
2430.0
0
D
Stock Option (Right To Buy)
11.23
2021-01-08
4
M
0
3825
11.23
D
2027-01-02
Common Stock
3825.0
0
D
Stock Option (Right To Buy)
18.01
2021-01-08
4
M
0
10500
18.01
D
2028-01-03
Common Stock
10500
3500
D
Stock Option (Right To Buy)
33.02
2021-01-08
4
M
0
9278
33.02
D
2029-01-21
Common Stock
9278
11932
D
Stock Option (Right To Buy)
43.69
2024-09-24
Common Stock
7000.0
7000
D
Stock Option (Right To Buy)
51.0
2025-01-02
Common Stock
1620.0
1620
D
Stock Option (Right To Buy)
40.1
2029-05-30
Common Stock
50000.0
50000
D
Stock Option (Right to Buy)
51.16
2030-01-28
Common Stock
64250
64250
D
Stock Option (Right to Buy)
66.49
2031-01-05
Common Stock
63000
63000
D
The transactions reported in this Form 4 were effected pursuant to written a Rule 10b5-1 plan adopted by the Reporting Person on May 20, 2020.
Currently exercisable.
This option was granted on January 3, 2018, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2019, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2019.
This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
This option was granted on May 31, 2019 and vests over four years, with 25% of the shares underlying the option vesting on May 31, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning August 31, 2020.
This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
/s/ Avraham S. Adler, attorney-in-fact
2021-01-12